Analyst consensus rating
Starling Oncology Analyst Rating: Strong Buy
Direct answer
Starling Oncology's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $9.25.
Forecast evidence checked November 13, 2026.
Get free Starling Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.75
- Average price target
- $9.25
- High price target
- $10.00
- Low price target
- $8.00
- Low target gap
- +113.3%
- Target upside
- +146.7%
- High target gap
- +166.7%
- Target range width
- 53.3%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Starling Oncology?
Starling Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $9.25.
How far are Starling Oncology's low and high targets from the recorded price?
The low target implies +113.3%, while the high target implies +166.7%.
How many analysts are included in Starling Oncology's consensus?
The verified consensus includes 4 analysts.
How is Starling Oncology's target upside or downside calculated?
The average target of $9.25 is divided by the recorded price of $3.75, then one is subtracted to produce +146.7%. This does not guarantee a future return.
When was Starling Oncology's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.